[go: up one dir, main page]

WO2001080871A3 - Anwendung von guanylat-zyklase-c (gc-c) agonisten als insulinotrope faktoren zur behandlung von diabetes mellitus typ 2 - Google Patents

Anwendung von guanylat-zyklase-c (gc-c) agonisten als insulinotrope faktoren zur behandlung von diabetes mellitus typ 2 Download PDF

Info

Publication number
WO2001080871A3
WO2001080871A3 PCT/EP2001/004538 EP0104538W WO0180871A3 WO 2001080871 A3 WO2001080871 A3 WO 2001080871A3 EP 0104538 W EP0104538 W EP 0104538W WO 0180871 A3 WO0180871 A3 WO 0180871A3
Authority
WO
WIPO (PCT)
Prior art keywords
agonists
treating diabetes
guanylate cyclase
diabetes type
insulinotropic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/004538
Other languages
English (en)
French (fr)
Other versions
WO2001080871A2 (de
Inventor
Urs Egner
Markus Meyer
Wolf-Georg Forssmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IPF Pharmaceuticals GmbH
Original Assignee
IPF Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IPF Pharmaceuticals GmbH filed Critical IPF Pharmaceuticals GmbH
Priority to AU2001256315A priority Critical patent/AU2001256315A1/en
Publication of WO2001080871A2 publication Critical patent/WO2001080871A2/de
Publication of WO2001080871A3 publication Critical patent/WO2001080871A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Arzneimittel enthaltend mindestens einen Guanylat-Zyklase-C Agonisten zur Behandlung von Diabetes Mellitus Typ 2.
PCT/EP2001/004538 2000-04-22 2001-04-21 Anwendung von guanylat-zyklase-c (gc-c) agonisten als insulinotrope faktoren zur behandlung von diabetes mellitus typ 2 Ceased WO2001080871A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001256315A AU2001256315A1 (en) 2000-04-22 2001-04-21 Use of guanylate cyclase-c (gc-c) agonists as insulinotropic factors for treating diabetes type 2

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10020028 2000-04-22
DE10020028.1 2000-04-22

Publications (2)

Publication Number Publication Date
WO2001080871A2 WO2001080871A2 (de) 2001-11-01
WO2001080871A3 true WO2001080871A3 (de) 2002-04-04

Family

ID=7639744

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/004538 Ceased WO2001080871A2 (de) 2000-04-22 2001-04-21 Anwendung von guanylat-zyklase-c (gc-c) agonisten als insulinotrope faktoren zur behandlung von diabetes mellitus typ 2

Country Status (2)

Country Link
AU (1) AU2001256315A1 (de)
WO (1) WO2001080871A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009033773A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use endothelin 2, alone or combined with a nonapeptide, a peptide as a therapeutic agent
KR20120115495A (ko) 2009-11-09 2012-10-18 아이언우드 파마슈티컬스, 인코포레이티드 위장 장애의 치료
JP5984675B2 (ja) 2009-12-07 2016-09-06 アイアンウッド ファーマシューティカルズ インコーポレイテッド 胃腸障害の療法
CA2835624A1 (en) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012155114A1 (en) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Peptides derived from uroguanylin and their use in gastrointestinal disorders
US9527887B2 (en) 2011-06-08 2016-12-27 Ironwood Pharmaceutical, Inc. Treatments for gastrointestinal disorders
US9617305B2 (en) 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4309815A1 (de) * 1993-03-26 1994-09-29 Forssmann Wolf Georg Verfahren zur Gewinnung und Anwendung des Guanylatzyklavaktivierenden Peptid I (GAP-I)
DE19543628A1 (de) * 1995-11-24 1997-05-28 Forssmann Wolf Georg Humanes, im Blut zirkulierendes Peptid mit insulinotroper Wirkung (GCAP-II-(89-112), (Guanylyl Cyclase C Aktivierendes Peptid II) und seine GCAP-Analoga, insbesondere das GCAP-I-(99-115), seine Anwendung als pharmakologischer Wirkstoff und Benutzung seines Wirkungsprinzipes zur Bereitstellung neuer GC-C-abhängiger insulinotroper Wirkstoffe
WO1999014239A1 (de) * 1997-09-12 1999-03-25 Wolf Georg Forssmann Zusammensetzung zur therapie von diabetes mellitus und fettsucht
DE19744027A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Substituierte Pyrazolo[3,4-b]pyridine, ihre Herstellung und Verwendung in Arzneimitteln

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4309815A1 (de) * 1993-03-26 1994-09-29 Forssmann Wolf Georg Verfahren zur Gewinnung und Anwendung des Guanylatzyklavaktivierenden Peptid I (GAP-I)
DE19543628A1 (de) * 1995-11-24 1997-05-28 Forssmann Wolf Georg Humanes, im Blut zirkulierendes Peptid mit insulinotroper Wirkung (GCAP-II-(89-112), (Guanylyl Cyclase C Aktivierendes Peptid II) und seine GCAP-Analoga, insbesondere das GCAP-I-(99-115), seine Anwendung als pharmakologischer Wirkstoff und Benutzung seines Wirkungsprinzipes zur Bereitstellung neuer GC-C-abhängiger insulinotroper Wirkstoffe
WO1999014239A1 (de) * 1997-09-12 1999-03-25 Wolf Georg Forssmann Zusammensetzung zur therapie von diabetes mellitus und fettsucht
DE19744027A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Substituierte Pyrazolo[3,4-b]pyridine, ihre Herstellung und Verwendung in Arzneimitteln

Also Published As

Publication number Publication date
WO2001080871A2 (de) 2001-11-01
AU2001256315A1 (en) 2001-11-07

Similar Documents

Publication Publication Date Title
EG24124A (en) Pharmaceutical compositions for the treatment of type-II diabetes mellitus
WO2004069158A3 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
EP1389621A4 (de) N-substituierte pyrazolyl-o-glykosidderivate und diese enthaltendes diabetesmittel
WO2002046227A3 (en) Glp-1 fusion proteins
BG103671A (en) Combinations of sulphonylcarbamide-glytazone having synergetic effect for the treatment of diabetes
AU2000276362A1 (en) Composition for the treatment of diabetes
CA2315767A1 (en) Autoclavable pharmaceutical compositions containing a chelating agent
CA2383983A1 (en) Substituted indolealkanoic acids
DE60110054D1 (en) Cardioprotektive phosphonate
MXPA02009773A (es) Derivados de indolin-2-ona y su uso como ligandos de receptores de ocitocina.
AU2002222932A1 (en) N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists
BR9910920A (pt) Composição não inflamável, e, processos de limpeza e de revestimento
AU2001273515A1 (en) Azolidines as beta-3 adrenergic receptor agonists
WO2002044113A3 (en) Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
WO2001080871A3 (de) Anwendung von guanylat-zyklase-c (gc-c) agonisten als insulinotrope faktoren zur behandlung von diabetes mellitus typ 2
WO2001000566A3 (en) Substituted phenoxyacetic acids
MXPA03007635A (es) P-tienilbencilamidas que sirven como agonistas de receptores para angiotensina-(1-7), metodo para su produccion, su uso y preparaciones farmaceuticas que las contienen.
TWI319762B (en) 1,7,8-trifluoro-2-naphthol and manufacturing methods for liquid crystal compositions containing the same
AU4681000A (en) Diagnostic assay for diabetes mellitus based on mutational burden
WO2004024066A3 (en) Method of treating diabetes and related conditions
WO2003020963A3 (en) Proteins in type 2 diabetes
WO2003048342A3 (en) Liquid yeast compositions
IL109866A (en) Crystalline 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine(+)L-hydrogentartrate its preparation and pharmaceutical compositions containing it
ZA200304312B (en) 1,2,4-Oxadiazole derivatives as hPPAR alpha agonists.
MXPA03006606A (es) Proceso para preparacion de analogos de indeno heterociclico.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP